Progress in research of antibacterial agents

Chinese Journal of Antibiotics

Volumn 27, Issue 2, 2002, Pages 67-79

  Zhang, Zhi Ping ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CEFCAPENE PIVOXIL; CEFDINIR; CEFDITOREN PIVOXIL; CEFEPIME; CEFETAMET PIVOXIL; CEFODIZIME; CEFOSELIS; CEFOTIAM; CEFOTIAM HEXETIL; CEFOZOPRAN; CEFPIROME; CEFPODOXIME PROXETIL; CEFPROZIL; CEFTEM; CEFTIBUTEN; CETHROMYCIN; CLARITHROMYCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DIRITHROMYCIN; ETIMICIN; FARRON; FROPENEM; HABEKACIN; KETOLIDE; LINEZOLID; LORACARBEF; MEROPENEM; PANIPENEM; PANIPENEM PLUS BETAMIPRON; PIPERACILLIN PLUS TAZOBACTAM; RIFABUTIN; SULOPENEM; TELIMYCIN; TELITHROMYCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; CONFERENCE PAPER; DRUG RESEARCH; DRUG SCREENING; MULTIDRUG RESISTANCE;

EID: 0036194952     PISSN: 10018689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (110)

1. Dirithromycin
2. Telithromycin (HMR3647) has significat clinical efficacy in the treatment of communityacquired rtis cause by Streptococcus pneomonia strain resestant to penicillin/or macrolids
3. Telithromycin
4. Rifabutin
5. Quinupristin/Dalfopristin. A review of its use in the management of serious Gram-positive infections
6. Treatment of CAPD-peritonitis due to glocopeptide-resistant enterococcus faecium quinupristin/dalfopristin
7. Double-blind, randomised multicentre study of Synercid (PR-59500) versus ceftriaxone in the treatment of acute gram-positive bacterial pneumonia
8. Diperamycin a new antimicrobial antibiotic produced by Streptomyces griseoaurantiacus MK-393-AF2
9. Hydrophobic derivatives of Glycopeptide antibiotic eremomycin active against VanA Enterococci
10. Kalimantacin A, B and C, novel antibiotics from Alcaligeneues sp. YL-02632S
11. Katanosin B and plusbacin A3: Inhibitors of cell wall synthesis in methicillin resistant staphylococcus auraus
12. Lactomycin, a uew antibacterial antibiotic produced by Streptomyces rishiriensis
13. Saccharomycins, novel heptadecaglycoside antibiotic produced by Saccharothrix espanaensis
14. The strocture of sulfomycin II and III
15. A new anti-MRSA antibiotic complox WAP-8294A
16. YM-47515, a novel isonitrile antibiotic from Micromonospora echinospora, subsp, echinospora
17. A new tricyclic fluoroquinolone, Rufloxacin (MF-934), with interesting antibacterial and pharmacokinetic characteristics
18. Trovafloxacin (CP-99219)
19. Moxifloxacin (Bay 12-8039)
20. Gatifloxacin
21. Brodimoprim in Respiratory Infection
22. Linezolid
23. Withdrawals without widespread disaster
24. Glaxo withdraws grepafloxacin worldwide
25. Clinafloxacin
26. HSR-903
27. Antimicrobial activity of DU-6859, a new potent fluroquinolone, against clinical isolates
28. DC-756
29. T-3811
30. In vitro and in vivo antifungal activity of DU-6859a, a fluroquno-one, in combination with amphatercin B and fluconazole against pathagenic fungi
31. Warner-Lambert drops clinafloxacin
32. Potent 6 G-desfluoro-8-methylquinolone as new lead compound in antibacterial chemotherapy
33. In vitro antibacterial activity of series of nonfluoroquinolones against quinolone-resistant isolates of methicillin-resistant Staphylococcus aureusc
34. In vitro antibacterial activity of series of nonfluoroquinolones against penicillin and quinolone-resistant strains of Streptococcus pneumoniae
35. In vitro antibacterial activity of a series of novel nonfluoroquinolone against bacterial pathogens
36. In vitro evaluation of ABT-719, a novel DNA gyrase inhibitor
37. Efficacies of ABT-719 and related 2-pyridones, members of a new class of antibacterial agents, against experimental bacterial infections
38. The 2-pyridone antibacterial agents: 8-Position modification
39. Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant Gram-positive bacterial infections
40. Identification of a novel oxazolidinoe (U-100480) with potant antimycobacterial activity
41. Safety and efficacy of linezolin in phase II stadies
42. Safety and tolerance of linezolid in phase II trials
43. New anti-MRSA agent, spiroisoxazole derivertive (KY-9) alone and synergism with other aminoglycoside antibiotics
44. Pharmacokinetic and in vivo efficacy evalution of novel class of quinoline-indole antibacterial agents
45. Structure-activity relationships of a new class of antibacterials: 3-Indolyl-2-tetrahydroquinolines
46. Anti-MRSA dihydrofolate reductase inhibitors: Synthesis and SAR
47. Anti-MRSA dihydrofolate reductase inhibitors: Biological characterizations
48. Synthesis and microbiological activity of pyrrole analogs of BM-212, a potent antitubercular agent
49. Chemotherapy for the 21st Century-Lesson from the 20th Century
50. Tripeptide LY-301621 and its diastereomers as Methicillin potentiators against methicillin resistant staphylococcus aureus
51. Novel and sterocontrolled synthesis of a potent broad spectrum β-lactamase inhibitor
52. Inhibition of tetracycline efflux antiport protein by 13-thiosubstituted 5-hydro-6-deoxytetraeyclines
53. Identification of a tetracycline efflux resistance reverser UK57562
54. An efflux pump inhibitor, MC-04124, enhances the activity of macrolides against Gram-negative bacteria
55. Inhibitors of efflux pumps in Pseudomonas aeuruginosa poten-tiate the activity of the fluoroquinolone antibacterial levofloxacin
56. Impact of MC-510027, a fungal efflux pump inhibitor, on the susec-ptiibility of clinical isolates of Candida spp. to antifungal agents